Issue link: https://www.e-digitaleditions.com/i/1482660
25 caregiver focus cannapatientcare.com october 2022 | cannabis patient care opportunity for these compassionate use single patient IND opportunities for patients," she said. The plan is to bring this cell treatment to market through FDA—both the supercharged natural killer cells that her com- pany owns the patents to, and the research Dr. Jewett has been doing over the last 30 years at UCLA, along with the cannab- inoid medicine that can be used with the natural killer cells treatment. "My ultimate goal is to have a cancer therapy, which would be a combinational therapy that does not make the pa- tient sick, and fixes the core reason they got cancer in the first place," said Ryan. Sophie has had two infusions in recent months: one in Sep- tember 2021 and the second in December 2021. "She has had 12 days of sickness since September, and that's it," Ryan said. "And even after this last infusion, Dr. Jewett continues to study her. Her blood and her immune system continue to function at ex- tremely high levels, even though she hasn't had a treatment since December." Ryan said that she, her husband Josh, and Sophie—working with Dr. Jewett—are optimistic that they will be able to erad- icate Sophie's disease especially after the enormous amount of shrinkage that they've seen. "I'm optimistic that we're go- ing to get rid of the disease," Ryan said. "After the amount of shrinkage we have continued to see scan after scan, we are confident we have fixed the immune system in her brain. This would be the first time that a low-grade glioma like this has been eradicated with the treatment." Broadening the Advocacy Work Ryan has spent the last nine years of her life traveling the world for speaking engagements to try and get the word out about case studies like Sophie's and other patients that they've treated. "Throughout this journey, not only has it helped Sophie and us believe that cannabis not only protects her body from the chemo and radiation, but it also helps her with side effects and immune stimulation," Ryan said. "She's also the happiest child you will ever meet in your entire life. And to watch Sophie be this vibrant, outgoing, spunky child when she's standing in a row of other cancer patients who are shy and recoiled and traumatized, that makes me hope everyone has an opportunity for their child to have a journey that's closer in replication to my own daughter's." Conclusion Sophie still remains on whole plant cannabis as well as a probi- otic bacteria called AJ4 that Dr. Jewett has created and that they are in the process of licensing at NKore BioTherapeutics. AJ4 is a probiotic that was developed by Dr. Jewett as a cancer treatment May 2021 images represent the tumor prior to NK Cell Treatment - Treatment 1 given Sept 2021 May 2022 images represent the tumor 5 months after 2nd infusion given in December 2021 Sophie R yan Brain MRI- Optic Pathway Glioma (incurable, low-grade brain tumor) August 2022 images represent the tumor 8 months after 2nd infusion given in December 2021 White chunky area is cancer Cystic Component Empty space is from a ressection Sophie Ryan's MRI displaying the tumor shrinkage.